Higher PLR and PHR Linked to Worse Systemic Sclerosis Activity
A case of systemic sclerosis. Source: Nevit Dilmen / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

Higher PLR and PHR Linked to Worse Systemic Sclerosis Activity

  Although the medical field has made significant strides over the years, there is still a lot we don’t know about the body. For example, what can we learn about…

Continue Reading Higher PLR and PHR Linked to Worse Systemic Sclerosis Activity
Belimumab Granted Orphan Drug Designation for Systemic Sclerosis
A case of systemic sclerosis. Source: Nevit Dilmen / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

Belimumab Granted Orphan Drug Designation for Systemic Sclerosis

Initially, belimumab (sold under the brand name BENLYSTA) was approved for the treatment of patients for lupus and lupus nephritis. It was the first FDA-approved biologic treatment within this indication.…

Continue Reading Belimumab Granted Orphan Drug Designation for Systemic Sclerosis
The Importance of Cancer Screenings in Patients with Scleroderma, Dermatomyositis
Elizabeth M. Dugan, Adam M. Huber, Frederick W. Miller, Lisa G. Rider / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

The Importance of Cancer Screenings in Patients with Scleroderma, Dermatomyositis

  This year, because of COVID-19, many healthcare-related events and symposiums have been moved online. However, that doesn't mean that the insights are any less helpful! In the virtual ACR…

Continue Reading The Importance of Cancer Screenings in Patients with Scleroderma, Dermatomyositis
Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study on Systemic Sclerosis
Pexels / Pixabay

Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study on Systemic Sclerosis

  A news release from Benzinga shares that biotechnology company Emerald Health Pharmaceuticals is beginning a Phase 2 clinical study on EHP-101 as a treatment for patients with systemic sclerosis.…

Continue Reading Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study on Systemic Sclerosis
ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
source: pixabay.com

ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma

CSL Behring has recently received the Orphan Drug designation for Privigen for the treatment of systemic scleroderma. Privigen has also been granted the Fast Track designation. This therapy has been…

Continue Reading ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins
PhotoLizM / Pixabay

Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins

According to a recent press release from XBiotech, a Texas-based biotechnology company, patient dosing is now underway in a phase 1 clinical study of the Company's investigational systemic sclerosis treatment, bermekimab.…

Continue Reading Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins
Study Findings Suggest Concentration of Immune Cells Could Help Predict Systemic Sclerosis
sabinurce / Pixabay

Study Findings Suggest Concentration of Immune Cells Could Help Predict Systemic Sclerosis

According to a publication from Scleroderma News, a recent study suggests that blood concentrations of certain immune cells could correlate with the severity of cases of systemic sclerosis. About Systemic…

Continue Reading Study Findings Suggest Concentration of Immune Cells Could Help Predict Systemic Sclerosis

“Stampede Scleroderma” Event for Systemic Sclerosis held at the Detroit Zoo Raised Over 130,000 Dollars for Research

Systemic Sclerosis Systemic Sclerosis (Systemic Scleroderma) is a rare disease which results in the hardening of the connective tissues in the body as well as the skin. It can affect…

Continue Reading “Stampede Scleroderma” Event for Systemic Sclerosis held at the Detroit Zoo Raised Over 130,000 Dollars for Research

Study Links IL-1 Cytokines to Increased Scarring in Systemic Scleroderma Patients

According to a publication from Scleroderma News, a study recently published in Clinical & Transitional Immunology suggests that certain cytokines (small proteins that play an important role in communication between…

Continue Reading Study Links IL-1 Cytokines to Increased Scarring in Systemic Scleroderma Patients